{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:01:27Z","timestamp":1792422087878,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ecl.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:06:17Z","timestamp":1773407177000},"page":"317-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pheochromocytomas and Paragangliomas"],"prefix":"10.1016","volume":"55","author":[{"given":"Hussam","family":"Alkaissi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans K.","family":"Ghayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2026.01.007_bib1","first-page":"16","article-title":"Das Ganglioma embryonale sympathicum (Sympathoma embryonale), eine typische b\u00f6sartige Geschwulstform des sympathischen Nervensystems","volume":"49","author":"Pick","year":"1912","journal-title":"Berlin Klin Wochenschr"},{"issue":"13","key":"10.1016\/j.ecl.2026.01.007_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa071407","article-title":"Evidence of MEN-2 in the original description of classic pheochromocytoma. Historical article research support, N.I.H., extramural research support, non-U.S. gov't","volume":"357","author":"Neumann","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-018-4181-2","article-title":"Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management, Review","volume":"35","author":"Jain","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. Practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9486","key":"10.1016\/j.ecl.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma. Review","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.maturitas.2013.12.009","article-title":"Pheochromocytoma: a review. Review","volume":"77","author":"Tsirlin","year":"2014","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"19","key":"10.1016\/j.ecl.2026.01.007_bib8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma. Research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, P.H.S","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2026.01.007_bib9","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1158\/1078-0432.CCR-09-1237","article-title":"Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Research support, non-U.S. gov't","volume":"15","author":"Erlic","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12022-008-9049-8","article-title":"First description of parathyroid disease in multiple endocrine neoplasia 2A syndrome","volume":"19","author":"Sisson","year":"2008","journal-title":"Endocr Pathol. Winter"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib12","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1210\/jc.2018-02102","article-title":"Fifty years after the first description, the MEN 2B syndrome diagnosis is still late: description of two recent cases","volume":"104","author":"Elisei","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1590\/abd1806-4841.20132125","article-title":"Neurofibromatosis: chronological history and current issues. Historical article","volume":"88","author":"Antonio","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcancer.2012.05.005","article-title":"Von Hippel-Lindau: how a rare disease illuminates cancer biology. Research Support, Non-U.S. Gov\u2019t Review","volume":"23","author":"Richard","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"5454","key":"10.1016\/j.ecl.2026.01.007_bib15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, P.H.S","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ecl.2026.01.007_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2350-6-39","article-title":"The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency","volume":"6","author":"Bayley","year":"2005","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ecl.2026.01.007_bib17","series-title":"GeneReviews((R))","article-title":"Hereditary paraganglioma-pheochromocytoma syndromes","author":"Else","year":"1993"},{"issue":"8","key":"10.1016\/j.ecl.2026.01.007_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, P.H.S","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/ERC-08-0214","article-title":"Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Case reports research support, N.I.H., intramural research support, non-U.S. gov't","volume":"16","author":"Ghayee","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.007_bib20","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2002-020312","article-title":"Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. Case reports","volume":"87","author":"Young","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9263","key":"10.1016\/j.ecl.2026.01.007_bib21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(00)04378-6","article-title":"Germline SDHD mutation in familial phaeochromocytoma. Letter research support, non-U.S. gov't","volume":"357","author":"Astuti","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc1013","article-title":"A role for mitochondrial enzymes in inherited neoplasia and beyond. Research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, non-P.H.S. research support, U.S. Gov\u2019t, P.H.S. review","volume":"3","author":"Eng","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Research support, non-U.S. gov't research support, N.I.H., extramural","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"3702","key":"10.1016\/j.ecl.2026.01.007_bib25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.150.3702.1464","article-title":"Adrenaline synthesis: control by the pituitary gland and adrenal glucocorticoids","volume":"150","author":"Wurtman","year":"1965","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma And\/Or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.007_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms. Review","volume":"15","author":"Soltani","year":"2015","journal-title":"J Diabetes Metab Disord"},{"issue":"20","key":"10.1016\/j.ecl.2026.01.007_bib28","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1056\/NEJMimc0806409","article-title":"Economy KE, Dec GW, jr. Interactive medical case. A crisis in late pregnancy. Interactive tutorial","volume":"361","author":"Ross","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11906-014-0442-z","article-title":"Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Review","volume":"16","author":"Pappachan","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.007_bib30","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma. Research support, non-U.S. Gov\u2019t review","volume":"60","author":"Eisenhofer","year":"2014","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/cen.70002","article-title":"Differences in clinical presentation between pheochromocytomas and paragangliomas","volume":"103","author":"Pihlblad","year":"2025","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2026.01.007_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1433582","article-title":"Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment","volume":"15","author":"Saavedra","year":"2024","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/heartjnl-2017-311579","article-title":"Acute stress-induced (takotsubo) cardiomyopathy. Review","volume":"104","author":"Dawson","year":"2018","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03346390","article-title":"The many faces of pheochromocytoma. Case reports","volume":"31","author":"Ghayee","year":"2008","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1210\/er.2002-0013","article-title":"Pheochromocytoma: State-Of-The-Art and future prospects","volume":"24","author":"Bravo","year":"2003","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.ecl.2026.01.007_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4065\/70.8.757","article-title":"Spells: in search of a cause. Case reports review","volume":"70","author":"Young","year":"1995","journal-title":"Mayo Clin Proc"},{"issue":"6560","key":"10.1016\/j.ecl.2026.01.007_bib37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/bmj.293.6560.1474-a","article-title":"Phaeochromocytoma in the elderly: a poorly recognised entity? Case reports research support, non-U.S. gov't","volume":"293","author":"Cooper","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2026.01.007_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.15.S1.1","article-title":"The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Guideline","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1530\/EC-18-0318","article-title":"Missed clinical clues in patients with pheochromocytoma\/paraganglioma discovered by imaging","volume":"7","author":"Rogowski-Lehmann","year":"2018","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7861\/clinmedicine.19-1-68","article-title":"Endocrinology: phaeochromocytoma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.007_bib42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","article-title":"International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents","volume":"20","author":"Casey","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib45","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/EJE-13-0882","article-title":"Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. Research support, non-U.S. Gov\u2019t review","volume":"170","author":"van Berkel","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1152\/physrev.00042.2006","article-title":"Catecholaminergic systems in stress: structural and molecular genetic approaches. Research support, N.I.H., extramural research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, non-P.H.S. review","volume":"89","author":"Kvetnansky","year":"2009","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib47","first-page":"3","article-title":"Should methoxytyramine routinely be included in the guidelines for biochemical assessment of pheochromocytomas and paragangliomas?","volume":"11","author":"Sweeney","year":"2025","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib50","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib51","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Research support, non-U.S. Gov\u2019t review systematic review","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Taieb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib53","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best? Evaluation studies multicenter study","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1011572617314","article-title":"Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Review","volume":"2","author":"Eisenhofer","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1210\/jc.2002-021251","article-title":"A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Comparative study","volume":"88","author":"Sawka","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6823-4-2","article-title":"A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma","volume":"4","author":"Sawka","year":"2004","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib57","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jcem.86.5.7496","article-title":"Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes","volume":"86","author":"Eisenhofer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/17446651.2014.887985","article-title":"Pheochromocytoma: pitfalls in the biochemical evaluation","volume":"9","author":"Dobri","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib59","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/HYPERTENSIONAHA.122.19019","article-title":"Improved diagnostic accuracy of clonidine suppression testing using an age-related cutoff for plasma normetanephrine","volume":"79","author":"Remde","year":"2022","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib60","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM198109103051107","article-title":"Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma","volume":"305","author":"Bravo","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.01.007_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.901760","article-title":"Biochemical diagnosis of catecholamine-producing tumors of childhood: neuroblastoma, pheochromocytoma and paraganglioma","volume":"13","author":"Eisenhofer","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2026.01.007_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2019.03.1620","article-title":"Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: particular importance for early infancy","volume":"494","author":"Peitzsch","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ecl.2026.01.007_bib63","series-title":"Williams textbook of endocrinology","author":"Melmed","year":"2011"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib64","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib65","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2018.06.018","article-title":"Optimized reference intervals for plasma free metanephrines in patients with CKD","volume":"72","author":"Pamporaki","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94104-9","article-title":"Optimized procedures for testing plasma metanephrines in patients on hemodialysis","volume":"11","author":"Pamporaki","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib67","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib68","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2214\/ajr.170.3.9490968","article-title":"CT time-attenuation washout curves of adrenal adenomas and nonadenomas","volume":"170","author":"Korobkin","year":"1998","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1148\/radiol.2342031876","article-title":"Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Comparative study evaluation studies","volume":"234","author":"Szolar","year":"2005","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00441-018-2791-4","article-title":"Molecular imaging and Theranostic approaches in pheochromocytoma and paraganglioma. Research support, N.I.H., intramural review","volume":"372","author":"Taieb","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tem.2005.01.007","article-title":"New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Review","volume":"16","author":"Ilias","year":"2005","journal-title":"Trends Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/110241598750004913","article-title":"Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French association of surgery (AFC), and the French association of endocrine surgeons (AFCE). Multicenter study","volume":"164","author":"Jalil","year":"1998","journal-title":"Eur J Surg"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10689-004-2155-y","article-title":"Imaging of pheochromocytoma and paraganglioma. Review","volume":"4","author":"Brink","year":"2005","journal-title":"Fam Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1148\/radiology.155.3.4001380","article-title":"Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Comparative study research support, non-U.S. Gov\u2019t research support, U.S. Gov\u2019t, P.H.S","volume":"155","author":"Lynn","year":"1985","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib75","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00006231-199207000-00006","article-title":"A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Review","volume":"13","author":"Solanki","year":"1992","journal-title":"Nucl Med Commun"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.007_bib76","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2967\/jnumed.108.052373","article-title":"Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. Comparative study research support, N.I.H., intramural","volume":"49","author":"Ilias","year":"2008","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.007_bib77","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1210\/clinem\/dgae252","article-title":"Approach to the patient: concept and application of targeted radiotherapy in the paraganglioma patient","volume":"109","author":"Pacak","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.007_bib78","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","article-title":"Choice is good at times: the emergence of [(64)Cu]Cu-DOTATATE-Based somatostatin receptor imaging in the era of [(68)Ga]Ga-DOTATATE","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.007_bib80","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/clinem\/dgaf259","article-title":"Approach to the patient with metastatic pheochromocytoma and paraganglioma","volume":"110","author":"Alkaissi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.007_bib81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/jch.12571","article-title":"Treatment of hypertension in children with catecholamine-secreting tumors: a systematic approach","volume":"17","author":"Romero","year":"2015","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cen.13252","article-title":"Is there an optimal preoperative management strategy for phaeochromocytoma\/paraganglioma? Review","volume":"86","author":"Challis","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib83","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient. Case reports research support, N.I.H., intramural review","volume":"92","author":"Pacak","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.ecl.2026.01.007_bib84","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMc1817267","article-title":"Ivabradine in catecholamine-induced tachycardia in a patient with paraganglioma. case reports letter","volume":"380","author":"Malaza","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.007_bib85","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4158\/EP14036.RA","article-title":"The Mount Sinai clinical pathway for the management of pheochromocytoma. Review","volume":"21","author":"Galati","year":"2015","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib86","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00000658-199011000-00010","article-title":"Surgical management of pheochromocytoma with the use of metyrosine. Clinical trial controlled clinical trial","volume":"212","author":"Perry","year":"1990","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/000313481808400642","article-title":"Predictive factors of operative hemodynamic instability for pheochromocytoma","volume":"84","author":"Aksakal","year":"2018","journal-title":"Am Surg"},{"issue":"16","key":"10.1016\/j.ecl.2026.01.007_bib88","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid cardiovascular response to belzutifan in HIF2A-Mediated paraganglioma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib89","first-page":"341","article-title":"[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. Clinical trial comparative study randomized controlled trial","volume":"30","author":"Schuttler","year":"1995","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12022-025-09884-x","article-title":"Correction: presurgical succinate MetAstatic risk tool (P-SMART) in paragangliomas","volume":"36","author":"Rapizzi","year":"2025","journal-title":"Endocr Pathol"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.007_bib91","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib92","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. meta-analysis review systematic review","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. Case reports","volume":"94","author":"Joshua","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.007_bib94","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. Research support, N.I.H., extramural","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib95","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. Case Reports Evaluation Studies","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib96","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae092","article-title":"A targetable receptor tyrosine kinase in metastatic pheochromocytoma and paraganglioma: a future journey for anlotinib?","volume":"8","author":"Alkaissi","year":"2024","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib97","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae061","article-title":"Anlotinib for metastatic progressed pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"8","author":"Tian","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2026.01.007_bib98","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0266","article-title":"A study on the efficacy and safety of anlotinib in patients with metastatic pheochromocytoma and paraganglioma","author":"Cui","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"10431","key":"10.1016\/j.ecl.2026.01.007_bib99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.007_bib100","first-page":"1","article-title":"Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P\/PG): preliminary results","volume":"33","author":"Pichun","year":"2015","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ecl.2026.01.007_bib101","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO-25-00791","article-title":"Erratum: phase II study of (177)Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Review","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.007_bib103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0969-8043(93)90179-E","article-title":"No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Research support, U.S. Gov\u2019t, P.H.S","volume":"44","author":"Vaidyanathan","year":"1993","journal-title":"Appl Radiat Isot"},{"issue":"25","key":"10.1016\/j.ecl.2026.01.007_bib104","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Clinical trial, phase II research support, N.I.H., extramural research support, non-U.S. gov't","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ecl.2026.01.007_bib106","article-title":"Belzutifan for HIF2A-Related pheochromocytoma and paraganglioma: a retrospective study of real-world data","author":"Alkaissi","year":"2025","journal-title":"Endocr Pract"},{"issue":"20","key":"10.1016\/j.ecl.2026.01.007_bib107","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.01.007_bib108","unstructured":"FDA approves belzutifan for pheochromocytoma or paraganglioma (2025)."},{"key":"10.1016\/j.ecl.2026.01.007_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103181","article-title":"Utility of disease probability scores to guide decision-making during screening for phaeochromocytoma and paraganglioma: a machine learning modelling cross sectional study","volume":"82","author":"Pamporaki","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.007_bib110","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.007_bib111","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.007_bib112","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.007_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101935","article-title":"Metabolomics and proteomics in pheochromocytoma and paraganglioma: translating biochemistry and biology to bedside","volume":"38","author":"Petrak","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.ecl.2026.01.007_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154297","article-title":"Targeting pheochromocytoma\/paraganglioma with polyamine inhibitors","volume":"110","author":"Rai","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib115","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ecl.2026.01.007_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217464","article-title":"Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models","author":"Uher","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ecl.2026.01.007_bib117","article-title":"Block, expose, and immunize: triple attack on cancer","author":"Honigova","year":"2025","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101941","article-title":"Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model","volume":"39","author":"Uher","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib119","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","article-title":"Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis","volume":"79","author":"Ghosal","year":"2023","journal-title":"Endocrine"},{"issue":"6220","key":"10.1016\/j.ecl.2026.01.007_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"28","key":"10.1016\/j.ecl.2026.01.007_bib121","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO-25-00791","article-title":"Phase II study of (177)Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib122","first-page":"658","volume":"25","author":"Jimenez","year":"2024","journal-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial, Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.007_bib123","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG Therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.007_bib124","article-title":"(177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS centre of excellence","volume":"5","author":"Shekhda","year":"2025","journal-title":"Endocr Oncol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:42Z","timestamp":1781621562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889852926000071"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pheochromocytomas and Paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}